Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 25, 2023
Daily News
December 25, 2023
- Kaigen Pharma Hit by Suspension Order for Decades of Illicit Manufacturing
December 25, 2023
- MHLW Budget Hits Record High at 33.8 Trillion Yen, Ups Funding for Drug Innovation
December 25, 2023
- (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
- MHLW Announces “Innovation Box” Tax Regime: FY2024 Reform
December 25, 2023
- Manabu Chikumoto to Helm Mitsubishi Chemical Group from April
December 25, 2023
- Japan Approves Label Expansions for Rexulti, Rituxan, and More
December 25, 2023
- Rune Ejler Andersen Tapped as Japan Chief of Lundbeck
December 25, 2023
- Japan Grants Orphan Tags to Keytruda, Teprotumumab, and 3 More Drugs
December 25, 2023
- Astellas Closes Buyout of US Prostate Cancer Drug Maker Propella
December 25, 2023
- Meiji’s Kostaive Booster Dose Non-Inferior to Pfizer COVID Jab: PIII Data
December 25, 2023
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…